Publications: 506 in 2026-03. +8.8% share of all MeSH-indexed PubMed records vs the same month last year (474 in 2025-03).
PublicationsPubMed
5062026-03
+8.8% share of all MeSH-indexed PubMed records vs same month last year (474 in 2025-03)provisional · settling
0.45% share
The most recent PubMed months are still being indexed. This number will change as they settle.
Counts PubMed records indexed under this disease's MeSH heading, by the month each record was published, as a share of all MeSH-indexed PubMed records that month. MeSH indexing lags about 5 months behind publication; the newest months are still filling in.
You may reuse this chart in your own work as long as the credit line stays intact.
Clinical trials: 21 in 2026-08. -40.0% vs the same month last year (35 in 2025-08).
Clinical trialsClinicalTrials.gov
212026-08
-40.0% vs same month last year (35 in 2025-08)
Counts clinical trials newly registered on ClinicalTrials.gov, by the date each registration was first posted. Scope is global, with no country filter.
You may reuse this chart in your own work as long as the credit line stays intact.
NIH grants: 199 in 2026-08. No percentage shown. No percentage shown: fewer than 24 months on record. The count is ranked in the history held. NIH grants: latest count 199 is in the 83rd percentile, running high, versus 15-mo window (2025 to 2026) (provisional, short baseline).
NIH grantsNIH RePORTER
1992026-08
83rd percentilerunning high, versus 15-mo window (2025 to 2026)short history
Counts NIH awards whose award notice is dated in the month, from NIH RePORTER, matched on the project text. Awards cluster at the end of the federal fiscal year. Scope is the United States. No investigator or contact data is collected.
Download ▾
You may reuse this chart in your own work as long as the credit line stays intact.
Patents: 657 in 2026-08. No percentage shown. No percentage shown: fewer than 24 months on record. The count is ranked in the history held. Patents: latest count 657 is in the 90th percentile, near its historical high, versus 15-mo window (2025 to 2026) (provisional, short baseline).
PatentsPatentsView / USPTO
6572026-08
90th percentilenear its historical high, versus 15-mo window (2025 to 2026)short history
Counts US pre-grant patent applications in the CPC classes mapped to this disease, by the date each application was published, as a share of all US pre-grant applications published that month. A publication reflects a filing about 18 months earlier. The CPC classes are broader than a single disease.
Download ▾
You may reuse this chart in your own work as long as the credit line stays intact.
Preprints: 32 in 2026-08. No percentage shown. No percentage shown: fewer than 24 months on record. The count is ranked in the history held. Preprints: latest count 32 is in the 30th percentile, in its typical range, versus 15-mo window (2025 to 2026) (provisional, short baseline).
PreprintsmedRxiv / bioRxiv
322026-08
30th percentilein its typical range, versus 15-mo window (2025 to 2026)short history
Counts new medRxiv and bioRxiv preprints whose title or abstract matches this disease, by posting date, deduplicated across the two servers. History starts at each server's first paper, 2013 for bioRxiv and 2019 for medRxiv. Scope is global. The only author detail kept is the corresponding author's institution.
You may reuse this chart in your own work as long as the credit line stays intact.
How unusual is this?
Each signal's latest reading ranked against this disease's own history
Publications
Publications: latest count 506 is in the 80th percentile, running high, versus 320 months since 2000.
80thpercentile
running high
506/mo · higher than 79% of 320 months since 2000
Clinical trials
Clinical trials: latest count 21 is in the 67th percentile, in its typical range, versus 315 months since 2000.
67thpercentile
in its typical range
21/mo · higher than 65% of 315 months since 2000
NIH grantsprovisional
NIH grants: latest count 199 is in the 83rd percentile, running high, versus 15-mo window (2025 to 2026) (provisional, short baseline).
83rdpercentile
running high
199/mo · higher than 80% of 15-mo window (2025 to 2026)
Patentsprovisional
Patents: latest count 657 is in the 90th percentile, near its historical high, versus 15-mo window (2025 to 2026) (provisional, short baseline).
90thpercentile
near its historical high
657/mo · higher than 87% of 15-mo window (2025 to 2026)
Preprintsprovisional
Preprints: latest count 32 is in the 30th percentile, in its typical range, versus 15-mo window (2025 to 2026) (provisional, short baseline).
30thpercentile
in its typical range
32/mo · higher than 20% of 15-mo window (2025 to 2026)
Publications and Clinical trials are ranked against every month since 2000. NIH grants, Patents and Preprints are ranked against the 15 months we hold and are marked provisional until the full history is loaded.
Recent history
All five signals on a shared 2025 to 2026 window, scoped to the youngest source so each reads at a comparable scaleDownload ▾
You may reuse this chart in your own work as long as the credit line stays intact.
Plot scoped to 2025 to 2026. True monthly spans by source: Publications 2000 to 2026 · 320 mo; Clinical trials 2000 to 2026 · 315 mo; NIH grants 2025 to 2026 · 15 mo; Patents 2025 to 2026 · 15 mo; Preprints 2025 to 2026 · 15 mo.
Publications2000 to 2026 · 320 mopeak 923/mo
Clinical trials2000 to 2026 · 315 mopeak 57/mo
NIH grants2025 to 2026 · 15 mobackfill pendingpeak 243/mo
Patents2025 to 2026 · 15 mobackfill pendingpeak 855/mo
Preprints2025 to 2026 · 15 mobackfill pendingpeak 46/mo
Plotted for 2025 to 2026. All five lines share one scale. Row labels show the full span.
Who's driving this
Top organizations behind each signal
Publications
Author institutions · 2025-04..2026-06
8%of works have an industry affiliation
Chinese Academy of Medical Sciences & Peking Union Medical College91
University of Amsterdam90
Heidelberg University81
Johns Hopkins University80
Amsterdam University Medical Centers77
Clinical trials
Lead sponsors · 2023-09..2026-08
29%industry-led in 2026-08
Fudan UniversityAcademic/other31
Ruijin HospitalAcademic/other23
Zhejiang UniversityAcademic/other20
Changhai HospitalAcademic/other17
Tianjin Medical University Cancer Institute and HospitalAcademic/other15
NIH grants
Funded institutions · 2025-06..2026-08
1,687awards in window
JOHNS HOPKINS UNIVERSITYMD · $32.3M · R01/P3062
UNIVERSITY OF TX MD ANDERSON CAN CTRTX · $40.8M · R01/R3757
UNIVERSITY OF MICHIGAN AT ANN ARBORMI · $20.6M · R01/F3149
STANFORD UNIVERSITYCA · $27.1M · R01/P3048
WASHINGTON UNIVERSITYMO · $24.8M · U54/R0145
Patents
Applicants · 2025-06..2026-08
The Regents of the University of California86
Genentech, Inc.70
Hoffmann-La Roche Inc.69
Bristol-Myers Squibb Company64
BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM62
Would you read a monthly digest for Pancreatic Cancer?
We are gauging interest in a monthly summary of what moved: new publications, trials, grants, patents and preprints for Pancreatic Cancer. Nothing is sent yet. If enough people ask, we will build it and you will hear first. Your address is used for that and nothing else, and you can ask us to remove it at any time.
Noted. Thanks for the interest in Pancreatic Cancer.
How we map "Pancreatic Cancer"
We used the following search terms for our data.
Publications (PubMed MeSH)
"Pancreatic Neoplasms"[MeSH Terms] (exploded), counted on the month's [dp] range; heading verified live 2026-09-10
Author institutions (OpenAlex)
topic T10231; search 'pancreatic cancer'
Clinical trials (ClinicalTrials.gov)
ConditionSearch: pancreatic cancer OR pancreatic ductal adenocarcinoma OR pancreatic neoplasm